Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

ContextVision shows strong momentum in Q4, leading to record sales for the year

STOCKHOLM – Feb 16, 2022- ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today reports its fourth quarter and full year 2021 results. Total sales 2021 reached 98.1 MSEK (94.7), which is the highest revenue in the history of the company. After a slow start to the year, each quarter’s sales have steadily increased, ending with a very strong Q4’s 27.4 MSEK (23.5). Total EBITDA ended at 2.2 MSEK and operating results reached -9.0 MSEK. Medical Imaging The year closed off with record

Eltel Group: Full-year January–December report 2021

October–December 2021 · Net sales EUR 226.3 million (229.2). Total growth -1.2% and organic growth1) in segments -3.1% · Operative EBITA2) EUR 7.0 million (4.0) and operative EBITA margin 3.1% (1.7) · Operative EBITA2) in segments EUR 7.3 million (6.0) and operative EBITA margin in segments 3.6% (2.9) · Items affecting comparability EUR 0.0 million (-5.7) · Operating result (EBIT) EUR 6.9 million (-1.9) and EBIT margin 3.1% (-0.8) · Net result EUR 4.1 million (-7.0) · Earnings per share EUR 0.02 (-0.05), basic and diluted · Cash flow from operating activities EUR

Navamedic ASA: Q4 2021 financial results

Oslo, 17 February 2022 - Navamedic ASA (OSE: NAVA) grew revenues by 63% in the fourth quarter of 2021 compared to the same quarter last year. The company reported revenues of NOK 90.2 million in the fourth quarter of 2021 with an EBITDA of NOK 7.6 million, driven by underlying growth in the portfolio and Mysimba® in particular. The company reiterates its mid-term ambition of building a NOK 500 million company through organic growth.“The fourth quarter of 2021 was strong for Navamedic, resulting in a full year growth of 33%, compared to our targeted growth rate of 20%. We have seen an

IMMray™ PanCan-d – peer-reviewed, blinded validation study now published in Clinical and Translational Gastroenterology

Peer-reviewed validation of study results demonstrating the IMMray™ PanCan-d blood test can detect PDAC with high specificity (99%) and sensitivity (92%), and a test specificity of 99% and sensitivity of 89% for PDAC stages I & II.LUND, SWEDEN – Immunovia AB (publ) announces that the peer-reviewed, blinded study to independently validate the clinical performance of IMMray™ PanCan-d has been published in Clinical and Translational Gastroenterology. The article is available online on the journal’s website. This publication expands on the findings announced on March 29, 2021, and they have now

Dignitana AB Publishes Q4 2021 Interim Report

Continued US growth fuels 25 percent revenue increase Financial highlights Q4 2021 · Net sales amounted to 16.2 MSEK (12.9), an increase of 25 percent over the same period 2020. · Operating result amounted to -11.4 MSEK (-19.7). · Net result after financial items amounted to -11.8 MSEK (-20.8). · Earnings per share were -0,18 SEK (-0,37). · Cash Balance amounted to 14.5 MSEK (78.8). · Average Daily Treatment Revenue (ADTR)* was 155 TSEK (130), an increase of 19 percent over the same period in 2020. Financial highlights January – December 2021 · Net sales

Citycon’s Financial Statements, Corporate Governance Statement and Remuneration Report for 2021 published

CITYCON OYJ   Stock Exchange Release   17 February 2022 at 09:00 hrsCitycon Oyj’s Financial Review for 2021 has been published today. The Financial Review includes the Report by the Board of Directors, Consolidated Financial Statements, Parent Company Financial Statements and Auditor’s Report for the accounting period 1 January – 31 December 2021.The Financial Statements are published in accordance with the European Single Electronic Format (ESEF) reporting requirements. The format is Extensible Hypertext Markup Language (XHTML), and the primary statements have been labelled with XBRL

Notice to Annual General Meeting of Kojamo plc

Kojamo plc Stock Exchange Release 17 February 2022 at 9:00 a.m. EETNotice to Annual General Meeting of Kojamo plc Notice is given to the shareholders of Kojamo plc to participate in the Annual General Meeting to be held on Wednesday 16 March 2022 at 10.00 a.m. (Finnish time) in Sanomatalo at Töölönlahdenkatu 2, FI-00100 Helsinki, Finland. In order to prevent the spread of the COVID-19 pandemic, the Annual General Meeting will be held without shareholders’ and their proxy representatives’ presence at the meeting venue. Shareholders of the company and their proxy representatives may

Veg of Lund AB: Year-end Report, January - December 2021

Several important agreements in place, significant interest in DUGOctober–December 2021 · Net sales for the fourth quarter amounted to TSEK 1,304 (352). · Operating profit before depreciation and amortization (EBITDA) amounted to TSEK -8,987 (-3,387), and EBIT amounted to TSEK -9,766 (-3,504). · Net profit amounted to TSEK -9,719 (-3,719). January–December 2021 · Net sales for the full year 2021 amounted to TSEK 2,573 (1,177). · Operating profit before depreciation and amortization (EBITDA) amounted to TSEK -22,500 (-17,325), and EBIT amounted to TSEK -23,641 (-17,785).

Terveystalo Plc: Notice to the Annual General Meeting 2022

Terveystalo Plc Stock Exchange Release 17 February 2022 at 9:00 EET   Notice is given to the shareholders of Terveystalo Plc (the "Company") to participate in the Annual General Meeting to be held on Thursday, 7 April 2022 at 3.00 p.m. (EEST) in the Company’s headquarters at Jaakonkatu 3 A, 6th floor, Helsinki, Finland. In order to prevent the spread of the Covid-19 pandemic, the Annual General Meeting will be held without shareholders’ and their proxy representatives’ presence at the meeting venue. Shareholders of the Company and their proxy representatives may participate in the

Ponsse to demonstrate the next generation harvester head

The launch of the completely upgraded PONSSE H8 harvester head will strengthen Ponsse’s position as one of the world’s leading suppliers of harvesting solutions. A powerful feed, firm grip and solid yet agile frame are characteristics of the H8 harvester head. Active Speed is available for the harvester head as a new feature, giving the harvester head a superior performance.Active Speed – improved productivity regardless of the stem size With Active Speed, the harvester head’s operating speed can be adjusted based on the tree species and stem diameter. Equipped with this new function,

Nixu Corporation’s Annual Report 2021 is published

Nixu Corporation, Stock exchange release, February 17, 2022 at 9:00 AM EETNixu Corporation has today published its Annual Report for the year 2021. The Annual Report contains an Annual review, the Report by the Board of Directors, the Financial Statements 2021, Auditor’s Report, the Corporate Governance Statement, and the Remuneration Report 2021. The Annual Report is published in accordance with the European Single Electronic Format (ESEF) reporting requirements. The format is Extensible Hypertext Markup Language (XHTML), and the primary statements have been labelled with XBRL tags. The

Stille AB: Year-End Report 2021

Stille AB (publ) publishes the report for the fourth quarter and the full year of 2021. ”Strong sales despite current market situation”, summarizes Stille CEO Hanna Ernestam Wilkman.Revenues for the fourth quarter reached 59.6 MSEK (45.0), including recently acquired S&T whose sales exceeded expectations. Excluding the acquisition sales amounted to 44.0 MSEK despite challenges in the US for both business units.  ”To strengthen growth in the US-market, we have in December launched a new general surgery table, GS2®, in an exclusive collaboration with GE Healthcare, and signed an exclusive

Oncopeptides publishes year-end report 2021

STOCKHOLM — February 17, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the year-end report 2021.Financial overview October-December · Net sales amounted to SEK -21.7 M (0.0) · Operating profit was SEK -389.8 M (- 511.6) · Net profit amounted to SEK -394.0 M (-513.0) · Profit per share, before and after dilution, amounted to SEK -5.23 (-7.59) · Cash balances at the end of the period amounted to SEK 362.2 M (840.3)  Financial overview

YIT’s Annual Review for 2021 published

YIT Corporation Stock Exchange Release 17 February 2022 at 9.00 a.m.YIT’s Annual Review for 2021 published YIT’s Annual Review for 2021 has been published today on the company’s website. The Annual Review consists of the highlights of 2021, report of the Board of Directors, consolidated financial statements, parent company’s financial statements, corporate governance statement and remuneration report. The report of the Board of Directors contains YIT’s statement of non-financial information. YIT publishes the Annual Review in accordance with European Single Electronic Format (ESEF)

Optomed Plc: Financial Statements Bulletin, January – December 2021

Optomed Plc         Stock Exchange Release    17 February 2022 at 9:00, Helsinki Optomed Plc: Financial Statements Bulletin, January – December 2021 October – December 2021 · Revenue decreased by 12.1 percent to EUR 3,552 (4,041) thousand · Devices segment revenue decreased by 23.6 percent to EUR 1,329 (1,738) thousand, as no camera deliveries were made to China during the quarter · Devices segment revenue continue strong growth in North America, Europe, and to the OEM channel · The Software segment revenue decreased by 3.5 percent to EUR 2,223 (2,303), as revenue from

Attana receives a Cell™ 250 instrument order from a European Life Science company

Attana has received an order for a Cell™ 250 instrument from a European Life Science company. This is the client’s second Attana instrument and is the result of a successful use and the client’s growth plans.The Cell™ 250 instrument will be installed during Q1 2022 and will positively affect Attana earnings in Q1 2022 and cash flow for the remainder of the year. “We strive to be close partner with our clients. This order is a result of this and our ability to grow together with our clients. We see good potential in increased further collaboration” comments Teodor Aastrup, CEO Attana.

Interim report Q4: A strong quarter ends a successful year

October – December 2021 · Net sales increased with 69 % and amounted to SEK 587 (348) million. · Organic growth amounted to 16 (25) %. · Adjusted EBIT increased to SEK 45 (8) million with a margin of 7.7 (2.4) %. · Profit for the period amounted to SEK 9 (1) million. · Earnings per share for the period before and after dilution amounted to SEK 0.16 (0.10). · The company’s B shares were listed during the quarter on Nasdaq Stockholm. In connection with the listing, a new share issue of SEK 528 million before transaction costs was made as well as an early redemption of the

Year-end report for Q4 and FY 2021

Profitable growth and very strong cash flow Quarter October-December 2021 · Net sales increased 5.9% to MSEK 641.4 (605.6) · The gross margin was 42.6% (40.3). · EBITA improved to MSEK 108.8 (77.4) · EBITA excl. items affecting comparability improved by MSEK 25.3 to MSEK 98.8 (73.5) · Net profit amounted to MSEK 75.6 (40.8) · Earnings per share amounted to SEK 4.68 (3.04) Full-year 2021 · Net sales rose 5.1% to MSEK 1,866.1 (1,774.9) · The gross margin was 38.4% (37.7) · EBITA improved to MSEK 124.1 (84.3) · EBITA excl. items affecting comparability

Year-end report for Duni AB (publ) January 1 – December 31, 2021

Growth with margins under pressureOctober 1 - December 31 · Net sales amounted to SEK 1,552 m (1,181), corresponding to a 31.4% increase in sales. Adjusted for exchange rate movements, net sales increased by 33.6%. · Strong growth towards a weak fourth quarter of 2020. · Earnings per share after dilution amounted to SEK 0.18 (0.73). · New restrictions and pressure on margins from sharp increases in raw material and logistics costs affected the quarter. January 1 – December 31 · Net sales amounted to SEK 5,061 m (4,501), corresponding to a 12.4% increase in sales.

Kojamo plc: Kojamo’s Board of Directors resolved on the long-term incentive plan’s performance period 2022–2024

Kojamo plc Stock Exchange Release, 17 February 2022 at 8:45 a.m. EETKojamo’s Board of Directors resolved on the long-term incentive plan’s performance period 2022–2024 Kojamo plc maintains a long-term incentive plan launched in 2021 for the group’s key employees with performance periods of 2021–2023, 2022–2024 and 2023–2025. The Board of Directors has resolved on the performance criteria, targets and target group for the performance period of 2022–2024. During the performance period of 2022–2024, the incentive plan is targeted at the members of the Management Team and other key

Year end report 2021 Scandinavian Biogas. New long-term target for 2030, 3 TWh biogas production, mainly Bio-LNG

Significant events in the fourth quarter of 2021 · Sales volumes for the period are the highest of the year. · Stable positive cash flow from operating activities. · In Sweden, the investment project Stockholm bio-LNG (liquid biogas) has been launched. · In Norway, the Skogn II project is on track, and the plant has received ISCC certification. · Klimatklivet has granted investment aid of SEK 154 million for the project in Mönsterås. RESULTS fourth QUARTER 2021 · Energy sold increased by 7.4% to 93.3 (86.9) GWh. · Net sales totalled SEK 104.8 (82.3) million,

CapMan Real Estate sells attractive high-street retail and office property in central Oslo

CapMan Real Estate press release 17 February 2022 at 8:30 am EET CapMan Real Estate sells attractive high-street retail and office property in central Oslo CapMan Nordic Real Estate II Fund has sold the 4,700 sqm property Lille Grensen 5 located in central Oslo to Arctic Securities for NOK 488 million. The property was originally acquired by CapMan Real Estate in December 2017. Since acquisition, the fund has signed several leases with new well-known tenants, carried out substantial refurbishment works and transformed the property to a core asset with long stable income. “

Apetit Group’s profitability lower than in the previous year – Positive overall development in Food Solutions

Apetit Plc, Financial Statements Review on 17 February 2022 at 08:30 a.m.Apetit Plc: Financial Statements Release 1 January to 31 December 2021 Apetit Group’s profitability lower than in the previous year – Positive overall development in Food Solutions October–December 2021, continuing operations* · Net sales amounted to EUR 83.0 (82.0) million · EBITDA was EUR 2.2 (2.7) million · Operating profit was EUR 0.5 (1.1) million January–December 2021, continuing operations* · Net sales amounted to EUR 283.9 (292.9) million · EBITDA was EUR 9.2 (10.1) million ·

There are no items matching the current filter
There are no more items matching the current filter
Back to top